MARCO GENNARINI

PhD Student

PhD program:: XLI
email: marco.gennarini@uniroma1.it




supervisor: Prof.ssa Agnese Po
advisor: Prof.ssa Valeria Panebianco
co-supervisor: Prof.ssa Lucia Manganaro

Research: Integrative Radiogenomic Approach to Predict Chemotherapy Response in Advanced High-Grade Serous Ovarian Cancer


MD – Board-Certified Specialist in Diagnostic Radiology

EDUCATION AND TRAINING

November 2025 – Present
PhD Program (41st cycle) in Network Oncology and Precision Medicine
Sapienza Università di Roma

November 2021 – October 2025
Residency in Diagnostic Radiology – Final grade: 70/70 with honors
Sapienza Università di Roma – Policlinico Umberto I

Specialization Thesis:
“Validation of radiomic models in magnetic resonance imaging for the classification and risk stratification of ovarian masses”
Supervisor: Prof. Lucia Manganaro

October 2012 – June 2021
MD Degree in Medicine and Surgery – Final grade: 107/110
Sapienza Università di Roma

Medical Degree Thesis:
“Risk factors for preterm birth: correlations with neonatal outcomes and preventive strategies”
Supervisor: Prof. Pasquale Mancino

October 2020
Basic Life Support (BLS) Certification
American Heart Association

PROFESSIONAL EXPERIENCE

November 2021 – October 2025
Resident in Diagnostic Radiology
Sapienza Università di Roma – Policlinico Umberto I

Clinical and research activities with particular focus on:

Oncologic CT and MRI imaging

Female urogenital imaging

Obstetric and fetal imaging

Multiparametric MRI (DWI, ADC, IVIM)

Radiomics and quantitative imaging analysis

Assessment of therapeutic response in gynecologic oncology

September 2021 – October 2021
Vaccination Physician – SARS-CoV-2 National Vaccination Campaign
ACEA Pfizer Vaccination Hub, Rome

Administration of COVID-19 vaccines, pre-vaccination clinical assessment, informed consent management, and post-vaccination monitoring within the Italian national vaccination program.

SPECIFIC SKILLS
Clinical Radiology Expertise

Oncologic CT and MRI

Female urogenital imaging (ovarian, endometrial, and cervical malignancies)

Obstetric and fetal MRI

Multiparametric MRI (DWI, ADC mapping, IVIM)

Imaging-based assessment of treatment response in gynecologic oncology

Quantitative Imaging and Radiomics

Radiomic feature extraction and analysis

Use of DeepTrace – Trace4Research platform

Tumor segmentation and ROI-based quantitative analysis

Integration of imaging data with clinical and molecular datasets

Information Systems

Advanced use of multiple hospital RIS and PACS systems

Clinical-radiological database management for retrospective and prospective studies

Research Skills

Design of clinical-radiological studies

Critical appraisal of scientific literature

Scientific manuscript preparation

Research activity in radiomics and radiogenomics

RESEARCH ACTIVITY
PhD Project

Title:
"Integrative Radiogenomic Approach to Predict Chemotherapy Response in Advanced High-Grade Serous Ovarian Cancer"

This PhD project is positioned within the field of precision oncology and aims to develop an integrated radiogenomic model in patients with advanced-stage high-grade serous ovarian cancer (HGSOC).

The study is prospective, monocentric, and designed to enroll 60 patients with newly diagnosed, histologically confirmed advanced HGSOC who are not eligible for primary cytoreductive surgery. All patients will undergo baseline CT and multiparametric MRI examinations.

Primary Objectives

To investigate associations between CT- and MRI-derived imaging biomarkers and:

Histopathological features

Serum biomarkers (CA-125, circulating miRNAs)

Tumor genomic profiles

To assess the prognostic value of radiogenomics in predicting chemotherapy response, measured by the Chemotherapy Response Score (CRS)

To identify correlations between radiomic signatures and chemotherapy resistance

Methodology

Multiparametric MRI (including DWI and quantitative analysis)

Texture analysis and radiomic feature extraction

Integration of radiological, histopathological, and genomic data

Development of predictive algorithms for:

Treatment response

Disease-Free Survival (DFS)

Overall Survival (OS)

The ultimate goal is to establish a prognostic radiogenomic signature capable of supporting therapeutic stratification and advancing personalized treatment strategies in advanced ovarian cancer.


Research products

Connessione ad iris non disponibile

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma